Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D09IRQ
|
|||
| Former ID |
DNCL001574
|
|||
| Drug Name |
Ataluren
|
|||
| Synonyms |
Ataluren; 775304-57-9; PTC124; 3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)benzoic acid; PTC-124; 3-[5-(2-Fluorophenyl)-1,2,4-oxadiazol-3-yl]benzoic acid; PTC124 (Ataluren); PTC 124; UNII-K16AME9I3V; Ataluren (PTC124); K16AME9I3V; NCGC00168759-02; Translarna; AK-31904; Benzoic acid, 3-[5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl]-; DSSTox_CID_26776; DSSTox_RID_81895; DSSTox_GSID_46776; Benzoic acid, 3-(5-(2-fluorophenyl)-1,2,4-oxadiazol-3-yl)-; CAS-775304-57-9; Ataluren [USAN:INN]; Translarna (TN); PTC124,Ataluren; Ataluren(ptc124)
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Cystic fibrosis [ICD-11: CA25; ICD-10: E84, E84.9; ICD-9: 277] | Phase 3 | [1] | |
| Dravet syndrome [ICD-11: 8A61.11] | Phase 2 | [2] | ||
| Muscular dystrophy [ICD-11: 8C70; ICD-10: G71.0] | Phase 2 | [2] | ||
| Aniridia [ICD-11: LA11.3; ICD-10: Q13.1] | Phase 1 | [1] | ||
| Mucopolysaccharidosis [ICD-11: 5C56.3; ICD-9: 277.5] | Phase 1 | [1] | ||
| Duchenne dystrophy [ICD-11: 8C70; ICD-10: G71.0] | Application submitted | [2] | ||
| Company |
Genzyme; PTC Therapeutics
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H9FN2O3
|
|||
| Canonical SMILES |
C1=CC=C(C(=C1)C2=NC(=NO2)C3=CC(=CC=C3)C(=O)O)F
|
|||
| InChI |
1S/C15H9FN2O3/c16-12-7-2-1-6-11(12)14-17-13(18-21-14)9-4-3-5-10(8-9)15(19)20/h1-8H,(H,19,20)
|
|||
| InChIKey |
OOUGLTULBSNHNF-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 775304-57-9
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
16302894, 23402844, 29203630, 42299455, 57304410, 57376289, 75766960, 85852879, 87334013, 96026003, 99373538, 99436942, 99460885, 103563347, 103910924, 109693655, 118049493, 123051056, 123121571, 124757874, 125164722, 125503240, 126582219, 126635177, 126666965, 126726702, 134964148, 135252715, 135727400, 136345855, 136367510, 136367810, 136376015, 136920369, 137053896, 138987465, 143497760, 144206184, 152213774, 152236440, 152258609, 152344272, 160647444, 160816445, 162037998, 162195922, 162912919, 163589943, 164825244, 170466862
|
|||
| ChEBI ID |
CHEBI:94805
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Dystrophin nonsense mutant (DMD) | Target Info | Modulator | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7341). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.